Clinical benefit (n=2) | No clinical benefit (n=11) | p-value | |
---|---|---|---|
Age | 47.0 (40.0) | 53.0 (46.0-54.0) | .641* |
Male | 2 (100%) | 8 (72.7%) | 1.0† |
Baseline ALC | 1.55 (1.30) | 1.40 (0.80-1.70) | .641* |
LDH | 277.5 (158.0) | 209.0 (151.0-286.0) | .641* |
Prior Treatments | 1/2 (50%) | 6/11 (54.5%) | 1.0† |
Metastatic Subsets | |||
Distant Nodes | 1 (50%) | 2 (18.1%) | .423† |
Lung +/− Distant Nodes | 0 | 5 (45.5%) | .487† |
Visceral | 1 (50%) | 4 (36.4%) | 1.0† |